The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Open accessAbstract
The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles published up to 8 June 2019, with no date limit on the indexed database. Clinical end points stratified by MRD status (positive or negative) were extracted, including hazard ratios (HRs) on PFS and OS, P values, and confidence intervals (CIs). HRs were estimated based on reconstructed patient-level data from published Kaplan-Meier curves. Forty-four eligible studies with PFS data from 8098 patients, and 23 studies with OS data from 4297 patients were identified to assess the association between MRD status and survival outcomes. Compared with MRD positivity, achieving MRD negativity improved PFS (HR, 0.33; 95% CI, 0.29-0.37; P < .001) and OS (HR, 0.45; 95% CI, 0.39-0.51; P < .001). MRD negativity was associated with significantly improved survival outcomes regardless of disease setting (newly diagnosed or relapsed/refractory MM), MRD sensitivity thresholds, cytogenetic risk, method of MRD assessment, depth of clinical response at the time of MRD measurement, and MRD assessment premaintenance and 12 months after start of maintenance therapy. The strong prognostic value of MRD negativity and its association with favorable outcomes in various disease and treatment settings sets the stage to adopt MRD as a treatment end point, including development of therapeutic strategies. This large meta-analysis confirms the utility of MRD as a relevant surrogate for PFS and OS in MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent data show that MRD negative status (as estimated by next generation molecular methods or flow cytometry) has favorable prognostic value and may be of value as a surrogate endpoint for clinical trials in myeloma.35,108,109”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [108]
In the citing paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [14]
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Guyot, P., Ades, A., Ouwens, M. J., & Welton, N. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-9 · Cited by 2,526
A comparison of heterogeneity variance estimators in simulated random‐effects meta‐analyses
Langan, D., Higgins, J. P. T., Jackson, D., Bowden, J., Veroniki, A. A., Kontopantelis, E., Viechtbauer, W., & Simmonds, M. (2019) · Research Synthesis Methods · doi:10.1002/jrsm.1316 · Cited by 1,074 · cited 1×
“Heterogeneity in design and population among the studies eligible for meta-analysis was assessed with multiple estimators.(16) Differences within subgroups were tested for statistical significance with the (2-sided) log-rank test, and HRs with 2-sided 95% CIs were estimated with a Cox regression model.”
MethodDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationMcCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Self-citationFlores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V. H. J., Pérez-Morán, J.-J., Vidriales, M.-B., García-Sanz, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.29 · Cited by 676
Self-citationMunshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Self-citationPaiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 477
Self-citation
Research works printed but not linked: 4
- Solovev, 2017, Maintenance therapy with bortezomib in patients with multiple myeloma (MM) after ASCT and minimal residual disease (MRD), Haematologica, 102, E1295
- Popat, 2017, Outcomes of stratification to ASCT or not based on depth of response: results of a phase 2 trial assessing the impact of minimal residual disease (MRD) in multiple myeloma patients with deferred ASCT (PADIMAC), Blood, 130, 1864
- Oliva, 2017, Minimal residual disease by multiparameter cytometry in transplant eligible patients with newly diagnosed multiple myeloma: results from the EMN02/HO95 phase 3 trial, Haematologica, 102, S102
- Austin, 2018, Sustained MRD negativity at 12 months post-ASCT predicts outcomes for myeloma patients: a real world study, EHA Library, 215626, 2018
Cited by
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
“Response depth and durability were related, as illustrated by the higher rates of PFS in patients with sCR and/or sustained MRD negativity.(22) All patient subgroups had high rates of response to cilta-cel, including those with plasmacytomas, high-risk cytogenetics, and ISS stage III.”
ResultSelf-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Kataoka, K., Yokota, M., Kato, K., Kotaka, M., Kagawa, Y., Yeh, K.-H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03254-6 · Cited by 255
“Additionally, the potential of MRD clearance as a surrogate endpoint of treatment efficacy and clinical outcomes in CRC, as demonstrated in leukemia and multiple myeloma 5,6 , warrants further investigation.”
Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B. R., Schmidt, T. M., Godby, K. N., Silbermann, R., Dhakal, B., Bal, S., Giri, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01935 · Cited by 267
“Any 123 (100) 91 (74) Hematologic Neutropenia 51 (41) 43 (35) Lymphopenia 34 (28) 27 (22) Anemia 26 (21) 13 (11) Thrombocytopenia 24 (20) 10 (8) Leukopenia 22 (18) 12 (10) Nonhematologic Fatigue 68 (55) 11 (9) Bone pain 68 (55) 7 (6) Rash maculopapular 50 (41) 5 (4) Nausea 49 (40) 0 Constipation 48 (39) 0 Upper respir…”
Metadata
- Authors
- Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., He, J., Heeg, B., Ukropec, J., Vermeulen, J., Cote, S., & Bahlis, N.
- Affiliations
- Harvard University (US)
- Unité de Génomique du Myélome, Institut Universitaire du Cancer de Toulouse (IUC-T) Oncopole, Toulouse, France;
- University of Calgary (CA)
- Navarre Institute of Health Research (ES)
- National and Kapodistrian University of Athens (GR)
- Ingress Health, Rotterdam, The Netherlands;
- Janssen Global Services, LLC, Raritan, NJ; and
- Janssen Global Medical Affairs, Horsham, PA
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-12-07
- Volume
- 4
- Issue
- 23
- Pages
- 5988-5999
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7724898
- OpenAlex
- W3111394247
- Cited by
- 431
- References
- 63
- Citations by year
- 2026: 63 · 2025: 88 · 2024: 88 · 2023: 79 · 2022: 65 · 2021: 46
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 BX000158)
- National Institutes of Health (PO1-155258, P50-100707)
- National Cancer Institute (P50CA100707, P01CA155258)
- Cilag
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, minimal residual disease, MRD negativity, progression-free survival, overall survival, prognostic factors, relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, maintenance therapy, cytogenetic risk
- MeSH terms
- Cytogenetics, Humans, Multiple Myeloma, Prognosis, Treatment Outcome, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020002827
- The paper
- Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., He, J., Heeg, B., Ukropec, J., Vermeulen, J., Cote, S., & Bahlis, N. (2020). A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020002827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.